In men and gender-diverse persons, twice-yearly subcutaneous lenacapavir vs. daily oral F/TDF reduced HIV incidence

Authors

Institutions

Publication Details

Journal
Annals of Internal Medicine
Published
2025-03-31
DOI
https://doi.org/10.7326/annals-25-00552-jc
Citations
1
Primary Topic
HIV/AIDS drug development and treatment
Type
article
Field-Weighted Citation Impact
1.40
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

In men and gender-diverse persons, twice-yearly subcutaneous lenacapavir vs. daily oral F/TDF reduced HIV incidence

Fred A. Zar
1 citations
Annals of Internal Medicine
HIV/AIDS drug development and treatment
1.40
article

In men and gender-diverse persons, twice-yearly subcutaneous lenacapavir vs. daily oral F/TDF reduced HIV incidence

Fred A. Zar
article en
1 citations

Abstract

No abstract available for this paper.
Annals of Internal MedicineVol. 178(4)
University of Illinois Chicago (US)
Gender equality
Openalex Percentile: Top 22%
HIV/AIDS drug development and treatment
1.40
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

In men and gender-diverse persons, twice-yearly subcutaneous lenacapavir vs. daily oral F/TDF reduced HIV incidence — Fred A. Zar · Annals of Internal Medicine (2025) | TGRS Research Map | TGRS